Long-term outcomes for patients recovering from hepatitis B related liver failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the long-term prognosis and risk factors for patients who have recovered from hepatitis B virus-related acute-on-chronic liver failure. It focuses on patients who survived more than 90 days post-hospitalization and analyzes their clinical data through retrospective methods. Additionally, the study includes follow-up surveys conducted via telephone to gather comprehensive long-term outcome data. The aim is to fill the gap in existing research regarding the long-term survival rates and prognostic factors for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age from 18 to 65 years old;
* The diagnosis consistent with hepatitis b associated chronic acute liver failure；
* After hospitalization, the survival time \> 90 days；
* The inpatient clinical data are complete.

Exclusion Criteria:

* Human immunodeficiency virus infection or congenital immune deficiency diseases;
* Liver cancer and other tumors, autoimmune liver disease, genetic and metabolic liver disease, or other serious diseases that significantly affect patient survival;
* Other conditions that the researchers judged not appropriate for inclusion.

Where it's running

• Third Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Liang Peng, Doctor — Third Affiliated Hospital, Sun Yat-Sen University
• Study coordinator: Lu Wang, Doctor
• Email: wanglu910525@163.com
• Phone: +8618814369232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment of Hepatitis B Related Acute-On-Chronic Liver Failure with Nucleotide/Nucleoside Analogues

  This study is testing if three antiviral medications can help people with hepatitis B-related liver failure feel better and improve their chances of recovery.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT03920618

• Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis

  This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.

  Recruiting Phase 4 Bangladesh Medical University · Dhaka, Dhaka Division · NCT07816094

• Hepatitis B in Zambia: an observational cohort of adults with HBV, with or without HIV

  This observational cohort follows adults diagnosed with hepatitis B in Zambia, with and without HIV coinfection, to see how their liver disease and HBV (and HIV when present) change over several years while they receive standard care.

  Recruiting at 3 sites University of Alabama at Birmingham · Lusaka and 2 other locations · NCT07589985

• Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.

  This project will look back at people with hepatitis B–related ACLF who received MSC infusions to see which factors affect whether the treatment helps.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07198854

• Long-term outcomes of pegylated interferon alfa-2b in families with clustered hepatitis B and high risk of cirrhosis or liver cancer

  This study will try pegylated interferon alfa-2b to see if it improves long-term outcomes for people with chronic hepatitis B from families where cirrhosis or liver cancer affects two generations.

  Recruiting First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi and 1 other locations · NCT07079150

• Comparing two treatments to prevent hepatitis B transmission from mothers to infants

  This study is testing whether two different antiviral treatments can help prevent pregnant women with high hepatitis B levels from passing the virus to their babies.

  Recruiting Guangzhou 8th People's Hospital · Guangzhou, Guangdong and 9 other locations · NCT06947356

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.